Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1-2):1-15.].
Porter
John B
JB
Taher
Ali T
AT
Cappellini
Maria D
MD
Vichinsky
Elliott P
EP
D001565:Benzoates / Q000009:adverse effects* / Q000191:economics* / Q000627:therapeutic use; D015913:Chelation Therapy / Q000009:adverse effects / Q000941:ethics*; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000627:therapeutic use; D016527:Drug Costs; D064420:Drug-Related Side Effects and Adverse Reactions / Q000188:drug therapy; D006402:Hematologic Diseases / Q000188:drug therapy*; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects* / Q000191:economics* / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D018570:Risk Assessment; D017262:Siderophores / Q000627:therapeutic use; D014230:Triazoles / Q000009:adverse effects* / Q000191:economics* / Q000627:therapeutic use
D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D017262:Siderophores; D014230:Triazoles; D000077543:Deferiprone; D003676:Deferoxamine; D000077588:Deferasirox